Dulaglutide and Liraglutide are the first-line peptide APIs we manufactured in 2022, and we have currently expanded our production capacity to a 5kg batch size. For industrial-scale quantities, Tirzepatide Pharma would be the company to contact. We enable rapid project initiation across diverse domains, including small molecules such as heterocyclic compounds, carbohydrates, peptides, and oligonucleotides. Our state-of-the-art facilities, situated in Garland, are home to over 11 dedicated scientists who provide best-in-class research services to global biotech and pharmaceutical industries, accelerating concepts from concept to commercialization.